Skip to main content
. 2021 Dec 2;11(12):e055832. doi: 10.1136/bmjopen-2021-055832

Table 1.

Characteristics and selected outcomes of enrolled patients

Derivation (n=21 743) Validation (n=5922)
Age in years, median (IQR) 57 (38–73) 56 (37–73)
Female (%) 10 992 (50.5) 3085 (52.1)
Arrival from, n (%)
 Home 19 879 (91.4) 5429 (91.7)
 Long-term care/rehabilitation facility/corrections facility 1000 (4.6) 262 (4.4)
 No fixed address/shelter/single room occupancy 574 (2.6) 201 (3.4)
 Interhospital transfer 290 (1.3) 30 (0.5)
Risk for infection, n (%)
 Healthcare worker 505 (2.3) 567 (9.6)
 Household/caregiver contact 566 (2.6) 161 (2.7)
 Institutional exposure (eg, LTC, prison) 1354 (6.2) 213 (3.6)
 Microbiology lab 4 (0.0) 8 (0.1)
 Travel 924 (4.2) 344 (5.8)
 Other 1320 (6.1) 449 (7.6)
 Unknown 5415 (24.9) 1856 (31.3)
 No documented risk for infection 10 028 (46.1) 1075 (18.1)
Arrival vital signs, median (IQR)
 Body temperature 36.7 (36.3–37.1) 36.8 (36.5–37.1)
 Heart rate 91 (79–107) 90 (78–105)
 Oxygen saturation 97 (95–98) 97 (95–99)
 Respiratory rate 18 (18–20) 18 (16–20)
 Systolic blood pressure 133 (118–150) 136 (120–149)
Common comorbid conditions, n (%)
 Active malignant neoplasm (cancer) 1678 (7.7) 333 (5.6)
 Asthma 1699 (7.8) 468 (7.9)
 Atrial fibrillation 1598 (7.3) 402 (6.8)
 Chronic kidney disease 1214 (5.6) 321 (5.4)
 Chronic lung disease (not asthma/pulmonary fibrosis) 1729 (8) 583 (9.8)
 Chronic neurological disorder (not dementia; eg, stroke/TIA, seizure disorder) 1310 (6) 400 (6.8)
 Congestive heart failure 1450 (6.7) 368 (6.2)
 Coronary artery disease 1591 (7.3) 449 (7.6)
 Dementia 734 (3.4) 188 (3.2)
 Diabetes 2583 (11.9) 916 (15.5)
 Dialysis 198 (0.9) 28 (0.5)
 Dyslipidaemia 2375 (10.9) 543 (9.2)
 Hypertension 6320 (29.1) 1697 (28.6)
 Hypothyroidism 1344 (6.2) 397 (6.7)
 Mild liver disease 280 (1.3) 90 (1.5)
 Moderate/severe liver disease 245 (1.1) 88 (1.5)
 Obesity (clinical impression) 284 (1.3) 108 (1.8)
 Organ transplant 128 (0.6) 19 (0.3)
 Rheumatological disorder 1122 (5.2) 258 (4.4)
 Other 10 075 (46.3) 2174 (36.7)
 Past malignant neoplasm (cancer) 936 (4.3) 256 (4.3)
 Psychiatric condition/mental health diagnosis 2967 (13.6) 831 (14)
 Pulmonary fibrosis 80 (0.4) 26 (0.4)
Symptoms reported, n (%)
 Abdominal pain 2725 (12.5) 540 (9.1)
 Altered consciousness/confusion 1456 (6.7) 322 (5.4)
 Bleeding (haemorrhage) 330 (1.5) 22 (0.4)
 Chest pain (includes discomfort or tightness) 4242 (19.5) 974 (16.4)
 Chills 2045 (9.4) 594 (10)
 Conjunctivitis 49 (0.2) 26 (0.4)
 Cough 7724 (35.5) 2663 (44.9)
 Diarrhoea 2140 (9.8) 526 (8.9)
 Dizziness/vertigo 1521 (7) 300 (5.1)
 Dysgeusia/anosmia 140 (0.6) 33 (0.6)
 Ear pain 144 (0.7) 30 (0.5)
 Fatigue/malaise 3361 (15.5) 924 (15.6)
 Fever 5055 (23.2) 1580 (26.7)
 Headache 2144 (9.9) 624 (10.5)
 Hemoptysis (bloody sputum) 298 (1.4) 66 (1.1)
 Joint pain (arthralgia) 296 (1.4) 82 (1.4)
 Lower chest wall indrawing 10 (0) 7 (0.1)
 Lymphadenopathy 67 (0.3) 21 (0.4)
 Muscle aches (myalgia) 1575 (7.2) 517 (8.7)
 Nausea/vomiting 4219 (19.4) 935 (15.8)
 No recorded symptoms 2113 (9.7) 431 (7.3)
 Runny nose (rhinorrhoea) 1061 (4.9) 501 (8.5)
 Seizures 205 (0.9) 42 (0.7)
 Shortness of breath (dyspnoea) 8537 (39.3) 2383 (40.2)
 Skin rash 241 (1.1) 38 (0.6)
 Skin ulcers 27 (0.1) <5
 Sore throat 3024 (13.9) 985 (16.6)
 Sputum production 1507 (6.9) 401 (6.8)
 Wheezing 582 (2.7) 130 (2.2)
Tobacco use, n (%) 1852 (8.5) 616 (10.4)
Illicit substance use, n (%) 1219 (5.6) 353 (6.0)
Oxygen required in ED, n (%) 1919 (8.8) 627 (10.6)
Hospital admission, n (%) 9913 (45.6) 2446 (41.3)
In-hospital death, n (%) 753 (3.5) 213 (3.6)
7-day average incident COVID-19 cases, median (IQR) 1.3 (0.73.2) 0.96 (0.5–1.3)
SARS-CoV-2 positive, n (%) 940 (4.3) 227 (3.8)

ED, emergency department; LTC, long-term care; TIA, transient ischaemic attack.